Physician profile
John J Mccarthy
NPI 1275578486
$860.54
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $67.61 · 2021: $25.43 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $282.99 | 2019-2022 | |
| Janssen Biotech, INC. | $145.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $120.84 | 2019 | |
| Celgene Corporation | $95.33 | 2019-2020 | |
| Amgen INC. | $55.25 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $32.28 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.04 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.27 | 2019 | |
| Seagen INC. | $14.14 | 2019 | |
| Dova Pharmaceuticals | $13.80 | 2019 | |
| Angiodynamics, INC. | $13.26 | 2019 | |
| Array Biopharma INC | $12.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.